Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
22 November 2023
Regulated information

Securities Note – November 2023 Open in new window

04 October 2023
Corporate presentations

CORPORATE PRESENTATION – OCTOBER 2023 Open in new window

18 September 2023
Financial statements and reports

2023 HALF-YEAR FINANCIAL REPORT Open in new window

11 September 2023
Corporate presentations

CORPORATE PRESENTATION – SEPTEMBER 2023 Open in new window

22 June 2023
General Assembly, General meetings

GenSight Biologics Resultats AGM 21 juin 2023 Open in new window

22 June 2023
General Assembly, General meetings

GenSight Biologics – 2023 Compensation Policies Open in new window

14 June 2023
Financial statements and reports, General Assembly, General meetings

Statutory auditors’ supplementary report dated 25 January 2022 Open in new window

14 June 2023
Financial statements and reports, General Assembly, General meetings

Statutory auditors’ supplementary report dated 23 March 2023 Open in new window

14 June 2023
Financial statements and reports, General Assembly, General meetings

Statutory auditors’ supplementary report dated 22 december 2022 Open in new window

14 June 2023
Financial statements and reports, General Assembly, General meetings

Supplementary report of the Board of Director dated 25 January 2023 Open in new window

  • View previous 9 articles
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 23
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page